News & Updates

Osimertinib reduces risk of metastasis, CNS progression in NSCLC

13 Dec 2024 by

Treatment with osimertinib following chemoradiotherapy (CRT) helps lower the risk of distant metastases and central nervous system (CNS) disease progression in patients with unresectable stage III epidermal growth factor receptor-mutated (EGFRm) nonsmall cell lung cancer (NSCLC), results of the phase III LAURA study have shown.

Osimertinib reduces risk of metastasis, CNS progression in NSCLC

13 Dec 2024

Ribociclib plus radiotherapy feasible in metastatic breast cancer

13 Dec 2024

The addition of CDK4/6 inhibitor ribociclib to palliative radiotherapy is relatively safe in patients with metastatic breast cancer, reports a study.

Ribociclib plus radiotherapy feasible in metastatic breast cancer

13 Dec 2024

Sacubitril/valsartan protects against chemo-induced heart damage

12 Dec 2024 by

Use of the common heart failure medication sacubitril/valsartan helps reduce cardiotoxicity in high-risk cancer patients undergoing anthracycline therapy, according to the results of the SARAH trial.

Sacubitril/valsartan protects against chemo-induced heart damage

12 Dec 2024

Metformin improves responses to chemotherapy in nondiabetic breast cancer

11 Dec 2024

Use of metformin in nondiabetic breast cancer patients improves their clinical and pathological response to neoadjuvant AC-T chemotherapy, reveals a recent study.

Metformin improves responses to chemotherapy in nondiabetic breast cancer

11 Dec 2024

Hyperthermic intraperitoneal chemotherapy beneficial in recurrent ovarian cancer

11 Dec 2024

Administering hyperthermic intraperitoneal chemotherapy (HIPEC) during cytoreductive surgery for recurrent ovarian cancer helps prolong overall survival, according to the results of the phase III open-label CHIPOR trial.

Hyperthermic intraperitoneal chemotherapy beneficial in recurrent ovarian cancer

11 Dec 2024

Lidocaine infusion of no help in gut function recovery after colon resection

08 Dec 2024

Perioperative administration of 2% intravenous lidocaine does not appear to have any positive impact on gut function recovery in patients who undergo elective minimally invasive colon resection, according to a study.

Lidocaine infusion of no help in gut function recovery after colon resection

08 Dec 2024

Trastuzumab shots for breast cancer deliver on cost savings

07 Dec 2024 by

Subcutaneous trastuzumab may be a cost-saving alternative to the intravenous formulation in the treatment of breast cancer patients in Singapore, according to a study.

Trastuzumab shots for breast cancer deliver on cost savings

07 Dec 2024

High-risk opioid use prevalent in patients with haematologic malignancy

06 Dec 2024

Many adult patients with haematologic malignancies (HM) have high-risk opioid use, which can increase their risk of opioid-related harms, reveals a study.

High-risk opioid use prevalent in patients with haematologic malignancy

06 Dec 2024

Colonoscopy intervals may be extended beyond 10 years for people at low CRC risk

06 Dec 2024

Negative colonoscopy screening findings appear to be associated with lower colorectal cancer (CRC) incidence and mortality for 20 years, and as such, rescreening intervals may be extended beyond the currently recommended 10 years for people with a low-risk profile, according to a study.

Colonoscopy intervals may be extended beyond 10 years for people at low CRC risk

06 Dec 2024

Original New Drug Application Approvals by US FDA (16-30 November 2024)

06 Dec 2024

New drug applications approved by US FDA as of 16-30 November 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 November 2024)

06 Dec 2024

News & Updates

Filter by Specialty:

Specialty:

Osimertinib reduces risk of metastasis, CNS progression in NSCLC

Osimertinib reduces risk of metastasis, CNS progression in NSCLC

Ribociclib plus radiotherapy feasible in metastatic breast cancer

Ribociclib plus radiotherapy feasible in metastatic breast cancer

Sacubitril/valsartan protects against chemo-induced heart damage

Sacubitril/valsartan protects against chemo-induced heart damage

Metformin improves responses to chemotherapy in nondiabetic breast cancer

Metformin improves responses to chemotherapy in nondiabetic breast cancer

Hyperthermic intraperitoneal chemotherapy beneficial in recurrent ovarian cancer

Hyperthermic intraperitoneal chemotherapy beneficial in recurrent ovarian cancer

Lidocaine infusion of no help in gut function recovery after colon resection

Lidocaine infusion of no help in gut function recovery after colon resection

Trastuzumab shots for breast cancer deliver on cost savings

Trastuzumab shots for breast cancer deliver on cost savings

High-risk opioid use prevalent in patients with haematologic malignancy

High-risk opioid use prevalent in patients with haematologic malignancy

Colonoscopy intervals may be extended beyond 10 years for people at low CRC risk

Colonoscopy intervals may be extended beyond 10 years for people at low CRC risk

Original New Drug Application Approvals by US FDA (16-30 November 2024)

Original New Drug Application Approvals by US FDA (16-30 November 2024)